- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases921
- Pathology818
- Mental Disorders743
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Nervous System Diseases921
- Pathology818
- Mental Disorders743
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- EGFR positive
- EGFR negative
- KRAS positive
- PR positive
- BRAF positive
- ALK negative
- ER negative
- PD-L1 negative
- PR negative
- CD20 positive
- BRAF negative
- BRCA1 positive
- ALK positive
- IDH positive
- BRCA2 positive
- ROS1 negative
- HLA positive
- p16 positive
- HLA-A positive
- ROS1 positive
- TP53 positive
- HR positive
- PIK3CA positive
- CD19 positive
- IDH negative
- MYC positive
- MET positive
- NF1 positive
- RET positive
- dMMR positive
- ANA positive
- KRAS negative
- MSI-H positive
- NRAS positive
- NTRK positive
- PALB2 positive
- anti-dsDNA positive
- MET negative
- MSS positive
- RAS positive
- p16 negative
- CFTR positive
- HBsAg positive
- HPV negative
- HPV positive
- RET negative
- TP53 negative
- pMMR positive
- ABCA4 positive
- BCL2 positive
- BCR-ABL1 positive
- CCND1 positive
- NTRK negative
- RAS negative
- RB1 positive
- anti-Sm positive
- ctDNA positive
- BCL6 positive
- BRCA1 negative
- BRCA2 negative
- CD123 positive
- COL7A1 positive
- DMD positive
- HLA negative
- HLA-A negative
- MGMT negative
- PTEN positive
- RB1 negative
- AKT negative
- APP positive
- BRCA positive
- CD30 positive
- DLL3 positive
- FLT3 positive
- FMR1 positive
- HR negative
- HRAS positive
- MDM2 positive
- MGMT positive
- MMR negative
- MSI-H negative
- NRAS negative
- PSEN1 positive
- PSEN2 positive
- PTCH1 positive
- Philadelphia chromosome positive
- PiZZ positive
- RF positive
- RHO positive
- SMARCA4 positive
- TROP2 negative
- TROP2 positive
- dMMR negative
- 11q negative
- 11q positive
- AKT positive
- ALPL positive
- APOL1 positive
- ARID1A positive
- ATM positive
- Anti-PLA2R positive
- Aβ1-42 positive
- B7-H3 positive
- C5 positive
- CAG repeat in HTT positive
- CD5 positive
- CLDN18.2 positive
- EBV DNA positive
- EBV positive
- FGFR2 positive
- FGFR3 positive
- FOXO1 fusion negative
- GPC3 positive
- GRN positive
- HBB positive
- HBV DNA negative
- HBsAg negative
- HEXA positive
- HEXB positive
- HPV16 positive
- IGHV positive
- JAK2 positive
- KIT positive
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- MSS negative
- MUC1 positive
- NF2 positive
- NPM1 positive
- NTRK1 positive
- NY-ESO-1 positive
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PMM2 positive
- PMS2 positive
- PTEN negative
- Ph positive
- RAF positive
- SMARCB1 negative
- SPINK5 positive
- T790M positive
- TET2 positive
- TTR positive
- UBA1 positive
- UGT1A1 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Smith positive
- t(11;14) positive
- 12 negative
- 12 positive
- 13q negative
- 13q positive
- 16p11.2 deletion positive
- 17p negative
- 17p positive
- 19q negative
- 19q positive
- 1p negative
- 1p positive
- 1p/19q co-deletion positive
- 1p/19q loss positive
- 1p36 deletion positive
- 46 XX karyotype positive
- 5q SMA positive
- 5q-autosomal recessive SMA positive
- AAVrh74 antibody titers negative
- ABL-class fusion positive
- ABL-class fusions positive
- ABO negative
- ABO positive
- ACVR1 positive
- AChR positive
- AChR-Ab positive
- ADAMTS-13 negative
- ADAMTS-13 positive
- AFP positive
- AKT1 E17K positive
- AKT1 positive
- ALT positive
- APC positive
- APOE e4 positive
- ASXL1 positive
- ATA positive
- ATN1 positive
- ATXN2 positive
- Acetylcholine receptor antibody positive
- Anti-CCP-2 positive
- Anti-HBc IgM negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Therapy (except reconstruction)
- Anti-Seizure Medications (up to 2 types)
- Any Treatment for Pancreatic Cancer
- At least one prior tumor-directed therapy
- Avoidance of Activities That Cause Joint Pain
- Biologic Anti-Neoplastic Agent
- CD4+ > 350 cells/microliter for at least twelve months
- Cancer-Directed Surgery
- Cellular Therapies for ALS
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6109 trials
Reading, PA (<10 mi)
Waitlist
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called IW-3300 to see if it can help people with chronic bladder pain. The drug is given as a rectal foam and aims to relieve symptoms like pain, burning, and pressure. Patients will use the drug at home for a few months.
Reading, PA (<10 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the addition of radiation therapy to the usual immunotherapy (with or without chemotherapy) treatment for patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) and who are also negative for a molecular marker called PD-L1.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to test a new eye examination tool called Welch Allyn PanOptic Plus Ophthalmoscope with a smartphone adapter. They want to see if this new device is better than the traditional eye
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares remibrutinib and teriflunomide in patients with relapsing multiple sclerosis. It aims to find out which medication is more effective and safer. Both drugs work by controlling the immune system to reduce relapses. Teriflunomide is an approved treatment for adults with this condition.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
West Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
West Reading, PA (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a vaccine to protect older adults from serious E. coli infections. The vaccine trains the immune system to recognize and fight off nine types of harmful E. coli bacteria. In earlier studies, a similar vaccine caused fever and/or diarrhea in some participants and provided limited protection against illness.
Efficacy & Safety Awards
Pivotal Trial
Wyomissing, PA (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will evaluate the efficacy and safety of elagolix in combination with COC compared to placebo in women with endometriosis.
Efficacy & Safety Awards
Pivotal Trial
West Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Non-Hodgkin's Lymphoma trials are postedWe'll send you an email whenever new trials are posted
West Reading, PA (<10 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is being conducted to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL).
Efficacy & Safety Awards
No Placebo-Only Group
West Reading, PA (<10 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether adding nivolumab to the usual treatment of encorafenib and cetuximab works better at shrinking tumors in patients with colorectal cancer that has spread or cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
West Reading, PA (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will compare whether Clofazimine Inhalation Suspension is better than a placebo when added to standard therapy for a specific condition in terms of effectiveness and safety.
Efficacy & Safety Awards
Pivotal Trial
West Reading, PA (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
West Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two types of radiation therapy for treating cancer that has spread to the brain. One type, called fractionated stereotactic radiosurgery (FSRS), delivers a high dose of radiation over
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
West Reading, PA (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medicine called ziltivekimab to see if it can help treat people who have had a heart attack. The goal is to see if ziltivekimab can
Efficacy & Safety Awards
Pivotal Trial
West Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is comparing the benefits of using chemotherapy along with immunotherapy (pembrolizumab) versus just using immunotherapy alone to treat patients with advanced lung cancer. The goal is to see
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
West Reading, PA (<10 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new blood test called Signatera to see if it can detect bladder cancer DNA in the blood. The test will be used to determine if patients who have had their bladder removed
Efficacy & Safety Awards
No Placebo-Only Group
West Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two different types of radiation therapy for high-risk prostate cancer. One type, called stereotactic body radiation therapy (SBRT), involves giving higher doses of radiation over a shorter period
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Breast Cancer trials are postedWe'll send you an email whenever new trials are posted
West Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing camizestrant, a drug that blocks estrogen, in patients with ER+/HER2- early breast cancer at medium to high risk of recurrence. The goal is to see if it works better than standard hormone treatments by stopping cancer cells from growing.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50